Business
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...
About this update from Moderna, Inc.
[{"type":"text","content":"Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure","length":123,"tagName":"p"},{"type":"text","content":"Partnership strengthens global preparedness against a significant pandemic threat","length":81,"tagName":"p"},{"type":"text","content":"If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing","length":206,"tagName":"p"},{"type":"text","content":"OSLO, NORWAY and CAMBRIDGE, MA / ACCESS Newswire / December 18, 2025 / The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase 3 clinical trial that aims to help advance Moderna's investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure. The funding marks a significant step forward in global pandemic preparedness that could enable fast, equitable access to vaccines for one of the world's most pressing health threats.","length":525,"tagName":"p"},{"type":"text","content":"This Phase 3 study would be the first mRNA-based vaccine targeting pandemic influenza to enter a pivotal trial. If the vaccine candidate is licensed, it would expand the current global portfolio of H5 vaccines with a rapid-response platform that could revolutionize future pandemic responses, making a significant contribution to CEPI's 100 Days Mission, a global goal to develop safe and effective vaccines within 100 days of a new pandemic threat being identified.","length":470,"tagName":"p"},{"type":"text","content":"Dr Richard Hatchett, Chief Executive Officer of CEPI said:","length":58,"tagName":"p"},{"type":"text","content":""Pandemic influenza remains one of the greatest threats to global health security. With this partnership, we are not just advancing vaccine science, we are fundamentally changing the game. By harnessing the speed and adaptability of mRNA technology, we could shave months off the response time, deliver vaccines at scale, and enable equitable access for all. This is how we plan to protect the world from the next flu pandemic."","length":438,"tagName":"p"},{"type":"text","content":"Stéphane Bancel, Chief Executive Officer of Moderna said:","length":57,"tagName...